Quantifying the psychological effects of ketamine: From Euphoria to the k-hole

Substance Use and Misuse

Volumn 45, Issue 14, 2010, Pages 2428-2443

  Stirling, John ^a   McCoy, Lauren ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

k hole experiences; ketamine; schizotypy

Indexed keywords

ANALGESIC AGENT; KETAMINE; STREET DRUG;

ADDICTION; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; FEMALE; HEALTH SURVEY; HUMAN; MALE; SCHIZOTYPAL PERSONALITY DISORDER; UNITED KINGDOM;

ANALGESICS; ENGLAND; FEMALE; HEALTH SURVEYS; HUMANS; KETAMINE; MALE; SCHIZOTYPAL PERSONALITY DISORDER; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 78049470951     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826081003793912     Document Type: Article

References (44)

1. Abi-Saab, W. M., D'Souza, D. C., Moghaddam, B., Krystal, J. H. (1998). The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharrmacopsychiatry, 31(2):104-109.
2. Adler, C. M., Malhotra, M. D., Elman, M. D., Goldberg, T., Egan, M., Pickar, D., et al. (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. American Journal of Psychiatry, 156;1646-1649.
3. Allen, R. M., Young, S. J. (1978). Phencyclidine-induced psychosis. American Journal of Psychiatry, 135(9):1081-1084.
4. Barkus, E., Lewis, S. (2008). Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychological Medicine, 38:1-10.
5. Barkus, E. J., Stirling, J., Hopkins, R. S., Lewis, S. (2006). Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology, 39(4):175-178.
6. Barkus, E., Stirling, J. Hopkins, R. S., Lewis, S. (2007). Cognitive and neural processes in non-clinical auditory hallucination. The British Journal of Psychiatry, 191:s76-s81.
7. Claridge, G., McCreery, C., Mason, O., Bentall, R., Boyle, G., Slade, P., et al. (1996). The factor structure of schizotypal traits: a large replication study. British Journal of Clinical Psychology, 35:103-115.
8. Copeland, J., Dillon, P. (2005). The health and psycho-social consequences of ketamine use. The International Journal of Drug Policy, 16(2):122-131.
9. Corlett, P. R., Honey, G. D., Aitken, M. R., Dickinson, A., Shanks, D. R., Absalom, A. R., et al. (2006). Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Archives of General Psychiatry, 63(6): 611-621.
10. Corlett, P. R., Honey, G. D., Fletcher, P. C. (2007). From prediction error to psychosis: ketamine as a pharmacological model of delusion. Journal of Psychopharmacology, 21(3):238-252.
11. Curran, H. V., Morgan, C. J. A. (2000). Cognitive, dissociative, and psychotogenic effects of ketamine on recreational users on the night of drug use and 3 days later. Addiction, 95:575-590.
12. Deakin, J. F. W., Lees, J., McKie, S., Hallack, J. E., Willimans, S. R., Dursan, S. M. (2008). Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Archives of General Psychiatry, 65(2):154-164.
13. Dillon, P., Copeland, J., Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug and Alcohol Dependence, 69:23-28.
14. Enarson, M. C., Hays, H., Woodroffe, M. A. (1999). Clinical experience with oral ketamine. Journal of Pain and Symptom Management, 17(5):384-386.
15. Fine, P. G. (1999). Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. Journal of Pain and Symptom Management, 17(4):296-300.
16. Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., et al. (2005). Psychological effects of (s)-ketamine and NNDimethyltryptamine (DMT): a double-bind crossover study in healthy volunteers. Pharmacopsychiatry, 38:301-311.
17. Jansen, K. L. R (1999). Ketamine and quantum psychiatry. Asylum Magazine, 11(3):19-21.
18. Jansen, K. L. R. (2001). Ketamine dreams and realities. Florida: Multidisciplinary Association for Psychedelic Studies.
19. Jansen, K. L. R., Theron, L. (2003). Ketamine: further observations on use, users, and consequences. Adicciones-Palma de Mallorca, 15(S2):135-166.
20. Javitt, D. C., Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148:1301-1308.
21. Jentsch, J. D., Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypo-function to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 30:201-225.
22. Krystal, J. H., Karper, L. P., Bennett, D., D'Souza, D. C., Abi-Dargham, A., Morrissey, K., et al. (1998). Interactive effects of sub-anasthetic ketamine and sub-hypnotic lorazepam in humans. Psychopharmacology (Berl), 135(3):213-229.
23. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51(3):199-214.
24. Lahti, A. C., Koffel, B., LaPorte, D., Tamminga, C. A. (1995). Sub-anaesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 13(1):9-19.
25. Lahti, A. C., Weiler, M. A., Michaelidis, T., Parwani, A., Tammminga, C. (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology, 25:455-467.
26. Lencz, T., Smith, C. W., Auther, A., Correll, C. U., Cornblatt, B. (2004). Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophrenia Research, 68:37-48.
27. Luisada, P. V., Brown, B. I. (1976). Clinical management of the phencyclidine psychosis. Clinical Toxicology, 9(4):539-545.
28. Moore, K., Measham, F. (2008). "It's the most fun you can have for twenty quid": motivations, consequences and meanings of British Ketamine use. Addiction Research and Theory, 16(3):231-244.
29. Morgan, C. J. A., Mofeez, A., Brandner, B., Bromley, L., Curran, H. V. (2004). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychophar-macology, 29:208-218.
30. Morgan, C. J. A., Muetzelfeldt, L., Curran, H. V. (2009). Ketamine use, cognition, and psychological well-being: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction, 104:77-87.
31. Pomarol-Clotet, E., Honey, G. D., Murray, G. K., Corlett, P. R., Absolom, A. R., Lee, M., et al. (2006). Psychological effects of ketamine in healthy volunteers: a phenomenological study. British Journal of Psychiatry, 189:173-179.
32. Radant, A. D., Bowdle, A., Cowley, D. S., Kharasch, E. D., Roy-Byrne, P. P. (1998). Does ketamine mediated N-Methyl-D-Aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology, 19(5):434-444.
33. Raine, A. (1991). The SPQ: a scale fro the assessment of schizotypal personality based on DSM III-R criteria. Schizophrenia Bulletin, 17(4):555-564.
34. Raine, A., Benishay, D. (1995). The SPQ-B: A brief screening instrument for schizotypal personality disorder. Journal of Personality Disorders, 9:346-355.
35. Reich, D. L., Silvay, G. (1989). Ketamine: an update on the first twenty-five years of clinical experience. Canadian Journal of Anaesthetics, 36:186-197.
36. Rowland, L. M., Bustillo, J. R., Mullins, P. G., Jung, R. E., Lenroot, R., Landgraf, E., et al. (2005). Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. American Journal of Psychiatry, 162(2):394-396.
37. Schneider, K. (1958). Clinical psychopathology (5th ed; trans M. W. Hamilton, 1959). New York: Grune-Stratton.
38. Sims, A. (2002) Symptoms in the mind (3rd ed). London: Saunders.
39. Stirling, J., Barkus, E. J., Nabosi, L., Irshad, S., Roemer, G., Schreudergoidheijt, B., et al. (2008). Cannabis-induced psychotic-like experiences are predicted by high schizotypy: confirmation of preliminary results in a large cohort. Psychopathology, 41(6):371-378.
40. Theberge, J., Al-Semaan, Y., Willianson, P. C., Menon, R. S., Neufeld, R. W., Rajakumar, N., et al. (2003). Glutamate and glutamine in the anterior cingulated and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. American Journal of Psychiatry, 160(2):2231-2233.
41. Tori,S. P. (1996).Ketamine abuse: "special K." Pennsylvania: Middle Atlantic-Great Lakes Organised Crime Law Enforcement Network (MAGLOCLEN).
42. Travis, A. (2005). Special K, the horse pill taking over from ecstasy among clubbers. Guardian, September 6. Retrieved August 27, 2007, from www.ketamine.com/special-k.html
43. Van Os, J., Bak, M., Hanssen, M., Bijl, J. L., De Graaf, R., Verdoux, H. (2002). Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology, 156;319-327.
44. WHO. (2006). Expert committee on drug dependence (ECDD): critical review of KETAMINE (34th report). Geneva: World Health Organisation.